Therapeutic potential of 4-1BB (CD137) as a regulator for effector CD8+ T cells

Journal of Hematotherapy and Stem Cell Research

Volumn 10, Issue 4, 2001, Pages 441-449

  Kim, Y J ^a,b   Broxmeyer, H E ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WALTHER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD137 ANTIGEN; INTERLEUKIN 4; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 4 1BB; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER IMMUNOTHERAPY; EFFECTOR CELL; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE SUBPOPULATION; TARGET CELL; VIRUS IMMUNITY;

EID: 0034880880     PISSN: 15258165     EISSN: None     Source Type: Journal    
DOI: 10.1089/15258160152509064     Document Type: Review

References (108)

1. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins
2. + T cells in the pathogenesis of organ-specific autoimmune diseases
3. In vivo tracking of tumor-specific T cells
4. + memory T cell subsets in persistent EBV infection are differentiated by migratory receptor expression
5. IL-12 and IFN-γ in host defense against mycobacteria and salmonella in mice and men
6. + T cells
7. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation
8. CD28/B7 system of T cell costimulation
9. CD28-mediated signaling co-stimulates murine T cells and prevents induction of anergy in T-cell clones
10. CD28 costimulation promotes the production of Th2 cytokines
11. Studies using antigen-presenting cells lacking expression of both B7-1 (CD80) and B7-2 (CD86) show distinct requirements for B7 molecules during priming versus restimulation of Th2 but not Th1 cytokine production
12. CD80 costimulation is required for Th2 cell cytokine production but not for antigen-specific accumulation and migration into the lung
13. Antigen-independent Th2 cell differentiation by stimulation of CD28: Regulation via IL-4 gene expression and mitogen-activated protein kinase activation
14. Differential T cell costimulatory requirements in CD28-deficient mice
15. + T cells
16. Faces and phases of human CD8 T-cell development
17. - T lymphocytes. Antigenic and functional properties
18. - T cells in healthy ageing people, including centenarians
19. Postthymic development of CD28-CD8+ T cell subset: Age-associated expansion and shift from memory to naive phenotype
20. - cytotoxic effector clones
21. Costimulation of CD8 αβ cells by NKG2D via engagement by MIC induced on virus-infected cells
22. Cord blood T lymphocytes lack constitutive perforin expression in contrast to adult peripheral blood T lymphocytes
23. - progeny, but IL-4 prevents loss of CD28 expression
24. - human T cells
25. + subsets defined by CD57, CD27, and CD45 isoforms
26. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
27. CD28-negative cytolytic effector T cells frequently express NK receptors and are present at variable proportions in circulating lymphocytes from healthy donors and melanoma patients
28. In vivo expression of natural killer cell inhibitory receptors by human melanoma-specific cytolytic T lymphocytes
29. + T-cell population
30. + T cells closely correlates with CD56 surface expression
31. + T cells
32. + NKT cells
33. + T cells rapidly acquire NK1.1 and NK cell-associated molecules upon stimulation in vitro and in vivo
34. + T cells expressing NK cell receptors in influenza A virus-infected mice
35. + T cells
36. On guard-activating NK cell receptor
37. Recognition of tumor cells by the innate immune system
38. + T cell differentiation: Initial antigen encounter triggers a developmental program in naive cells
39. Helper T cell differentiation is controlled by the cell cycle
40. Differentiation of naive CTL to effector and memory CTL: Correlation of effector function with phenotype and cell division
41. Persistence of memory CD8 T cells in MHC class I-deficient mice
42. + T cell responses
43. Human 4-1BB regulates CD28 co-stimulation to promote Th1 cell responses
44. Analysis of 4-1BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza virus
45. Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal
46. + T cells is induced by IL-2 receptor γ chain signaling cytokines and type I IFN, and increases susceptibility to activation-induced apoptosis
47. T cell co-stimulatory molecules other than CD28
48. The roles of Fas/APO-1 (CD95) and TNF in antigen-induced programmed cell death in T cell receptor transgenic mice
49. Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death
50. Immune privilege or inflammation? Insights into the Fas ligand enigma
51. Immune deviation and Fas-mediated deletion limit antitumor activity after multiple dendritic cell vaccinations in mice
52. + Tc1 cells: Loss of IL-2 synthesis and autonomous proliferation but retention of cytotoxicity and synthesis of other cytokines
53. + Tc1 cells induced by IL-4: Retained inflammation and perforin and Fas cytotoxicity but compromised long term killing of tumor cells
54. + T-cell responses
55. Enhanced cytotoxic T cell activity in IL-4-deficient mice
56. + Th1/Th2 T cells
57. Low dose TGF-β attenuates IL-12 responsiveness in murine Th cells
58. TGF-beta inhibits IL-12-induced activation of Jak-STAT pathway in T lymphocytes
59. Disruption of T cell homeostasis in mice expressing a T cell-specific dominant negative transforming growth factor β 11 receptor
60. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease
61. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors
62. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation
63. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies
64. 4-1BB ligand, a member of the TNF family, is important for the generation of antiviral CD8 T cell responses
65. Molecular and biological characterization of human 4-1BB and its ligand
66. 4-1BB T-cell antigen binds to mature B cells and macrophages, and costimulates anti-μ-primed splenic B cells
67. - T lymphocytes by 4-1BB ligand
68. 4-1BB costimulation is required for protective anti-viral immunity after peptide vaccination
69. + T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses
70. + cytotoxic T lymphocytes (CTL) but are not required for the maintenance of CTL memory following virus infection
71. CD40-CD40 ligand costimulation is required for generating antiviral CD4 T cell responses but is dispensable for CD8 T cell responses
72. Ox-40 ligand: A potent costimulatory molecule for sustaining primary CD4 T cell responses
73. OX40-deficient mice are defective in Th cell proliferation but are competent in generating B cell and CTL Responses after virus infection
74. Therapeutic vaccination for cancer
75. Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: Synergy with the CD28 co-stimulatory pathway
76. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine
77. Expression of co-stimulatory 4-1BB ligand induces significant tumor regression and protective immunity
78. + murine squamous cell carcinoma and the requirements of co-stimulatory molecules on tumour and host cells
79. Immunomodulatory gene therapy with interleukin 12 and 4-1BB ligand: Long-term remission of liver metastases in a mouse model
80. Interleukin-12: A proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity
81. Vaccines with interleukin-12-transduced acute myeloid leukemia cells elicit very potent therapeutic and long-lasting protective immunity
82. Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide-pulsed peripheral blood mononuclear cells by coadministration of recombinant murine interleukin-12
83. + T cells in vivo
84. + T cells
85. + T lymphocytes
86. IL-12 enhances CD8 T cell homeostasis expansion
87. Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation
88. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-γ production
89. + T cells that expands in patients receiving interleukin-12
90. Antitumor effects of interleukin-12 in pre-clinical and early clinical studies
91. The use of dendritic cells for cancer vaccination
92. + T cells
93. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming
94. Dendritic cells and immunotherapy for malignant disease
95. Dendritic cell vaccines for cancer immunotherapy
96. Dendritic cells in cancer immunotherapy
97. Developmental regulation of dendritic cell function
98. High level IL-12 production by murine dendritic cells: Upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10
99. CD4 T cell cytokine differentiation: The B cell activation molecule, OX40 ligand, instructs CD4 T cells to express interleukin 4 and upregulates expression of the chemokine receptor, Blr-1
100. Co-stimulation and selection for T-cell help for germinal centers: The role of CD28 and OX40
101. TGF-β1 prevents the noncognate maturation of human dendritic Langerhans cells
102. TGF-β1 regulation of dendritic cells
103. Analysis of expression and function of the costimulatory molecule 4-1BB in alloimmune responses
104. Ligation of 4-1BB (CDw137) regulates graft-versus-host disease, graft-versus-leukemia, and graft rejection in allogeneic bone marrow transplant recipients
105. Host T cells resist graft-versus-host disease mediated by donor leukocyte infusions
106. A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response
107. Relative diabetogenic properties of islet-specific Tc1 and Tc2 cells in immunocompetent hosts
108. 4-1BB costimulation promotes human T cell adhesion to fibronectin